BIOGRAPHICAL SKETCH. NAME: Chinazo O. Cunningham, MD, MS. era COMMONS USER NAME (credential, e.g., agency login): CHINAZO1

Transcription

1 BIOGRAPHICAL SKETCH OMB No /0002 (Rev. 08/12 Approved Through 8/31/2015) NAME: Chinazo O. Cunningham, MD, MS era COMMONS USER NAME (credential, e.g., agency login): CHINAZO1 POSITION TITLE: Associate Chief, General Internal Medicine; Professor of Medicine EDUCATION/TRAINING INSTITUTION AND LOCATION DEGREE Completion Date FIELD OF STUDY Northwestern University. Evanston, IL BA 06/1990 Psychology University of California, San Francisco (UCSF) MD 06/1994 Medicine UCSF Internal Medicine Residency Program Internship 06/1995 Internal Medicine New York University Internal Medicine Residency Program Residency 06/1998 Internal Medicine Chief Residency Albert Einstein College of Medicine, Bronx, NY MS 06/2008 Clinical research A. Personal Statement Since 2004, I have conducted clinical research and developed innovative treatment strategies to improve access to care and treatment outcomes among racial/ethnic minority drug users with or at-risk for HIV. Much of my work has involved developing and integrating innovative treatment interventions in primary care settings. My research projects have examined how health care interventions and treatment strategies affect treatment outcomes including pain, substance use, and HIV outcomes. Much of my work has focused on opioids, including pain management with opioid analgesics among HIV+ patients, buprenorphine and methadone treatment, financial incentives to reduce opioid and cocaine use, neurocognitive effects of opioid use, and medical cannabis s effect on opioids. I have served as a mentor to over 25 medical residents, fellows, and junior faculty, for which I have received national and local mentoring awards. I have been a mentor on 9 NIH-funded career development awards that focus on opioid prescribing, access to buprenorphine treatment, HCV treatment in primary care, linkage to HCV treatment after incarceration, medication adherence among HIV+ women of color, HIV health care utilization, and HIV testing in emergency departments. In addition, I have a K24 mid-career development award to mentor junior faculty in research focusing on drug use and HIV. I founded and direct the General Internal Medicine Fellowship Program and am Co-Director of Einstein s CFAR Development Core. I served on guideline committees focusing on opioid analgesic use for chronic pain (for the CDC) and pharmacologic treatment of opioid use disorder (for the American Society of Addiction Medicine). I served as a member of the NIH Office of AIDS Research s Racial and Ethnic Populations Committee, and currently serve as Chair of NY State Department of Health AIDS Institute s Substance Abuse Committee and Chair of the NIH s Behavioral and Social Consequences of HIV/AIDS Study Section. B. Positions and Honors Positions and Employment 1998-current Faculty, Internal Medicine Primary Care & Social Medicine Residency Programs, Montefiore Founder and Director, Montefiore/CitiWide Health Services Programs Montefiore Medical Center in collaboration with CitiWide Harm Reduction, Inc 2014-current Professor of Medicine, Family & Social Medicine, Psychiatry & Behavioral Sciences, Albert Einstein College of Medicine 2013-current Associate Chief, Director of Research Resources, Division of General Internal Medicine, Albert Einstein College of Medicine 2013-current Director, General Medicine Fellowship Program, Albert Einstein College of Medicine Other Experiences 2004-current Core Faculty, International AIDS Society USA

2 Ad Hoc Committee Member, Behavioral and Social Consequences of HIV/AIDS Study Section, NIH 2006 Ad Hoc Grant Review Committee Member, CDC, RFA for HIV, prisoners, and methamphetamines 2008 Grant Reviewer, American Foundations for AIDS Research (amfar) 2008 Expert Panelist, SAMHSA, Evaluation of Treatment Capacity Expansion/HIV 2008-current Buprenorphine Mentor, New York City Department of Health and Mental Hygiene Vice Chair, Substance Abuse Committee, New York State Department of Health, AIDS Institute Member, Racial and Ethnic Populations Ad Hoc Committee of the NIH Office of AIDS Research 2012-current Chair, Substance Abuse Committee, New York State Department of Health, AIDS Institute Standing member, Behavioral and Social Consequences of HIV/AIDS Study Section, NIH Member, Guideline Committee, Treatment of opioid addiction, American Society of Addiction Medicine Fellow of the Hedwig Van Ameringen Executive Leadership in Academic Medicine (ELAM) Program 2016 Member, Opioid Guideline Workgroup, Centers for Disease Control and Prevention s Guideline for Prescribing Opioids for Chronic Pain, Member, NYC Mayor s Ad-Hoc Heroin and Prescription Opioid Public Awareness Task Force 2016-currnt Member, Buprenorphine Steering Committee, NYC Department of Health and Mental Hygiene 2016-currnt Member, Buprenorphine Advisory Committee, NY State Department of Health, AIDS Institute 2016-current Chair, Behavioral and Social Consequences of HIV/AIDS Study Section, NIH 2017-current Member, Bronx District Attorney s Heroin Enforcement and Access to Treatment Working Group Honors 2000 Larry Linn Award, Society of General Internal Medicine Mary O Flaherty Horn Scholar, Society of General Internal Medicine 2007 Top reviewer, Annals of Internal Medicine (2007, 2012, 2015) 2008-current Featured in AHRQ s Health Care Innovations Exchange 2009 Inducted into the Northwestern University Athletic Hall of Fame 2009 Mentorship Award, Albert Einstein College of Medicine 2015 W. Anderson Spickard, Jr. Excellence in Mentorship Award, awarded by the Association of Medical Education and Research in Substance Abuse (AMERSA) 2015 Clinical Science Mentor of the Year, Albert Einstein College of Medicine C. Contribution to Science 1. Buprenorphine Treatment for Opioid Use Disorder: As the founder and director the Montefiore Buprenorphine Treatment Program, and the PI of several grants that have focused on buprenorphine treatment, I have contributed substantially to the field of office-based buprenorphine treatment. My work has focused on examining providers and patients barriers to buprenorphine treatment, improving access to buprenorphine treatment focusing on out-of-treatment injection drug users, and improving treatment outcomes by developing and testing innovative treatment strategies such as home-based inductions. Findings have demonstrated that despite poor and limited physician training to provide addiction treatment, providing buprenorphine treatment in primary care settings is feasible and associated with good outcomes. Additionally, many stipulations in initial national treatment guidelines were not supported by evidence, and my work helped to demonstrate the positive outcomes associated with home-based office inductions, and treatment of opioiddependent cocaine users and opioid-dependent patients with pain. These findings informed guidelines from the New York City Department of Health and Hygiene and the American Society of Addiction Medicine. a. Cunningham CO, Kunins HV, Roose RJ, Elam RT, Sohler NL. Barriers to Obtaining Waivers to Prescribe Buprenorphine for Opioid Addiction Treatment Among HIV Physicians. J Gen Intern Med Sep;22(9): Epub 2007 Jul 10. PMC b. Cunningham CO, Giovanniello A, Sacajiu G, Whitley S, Mund P, Beil R, Sohler NL. Buprenorphine treatment in an urban community health center: What to expect. Fam Med Jul-Aug;40(7): PMC c. Cunningham CO, Giovanniello A, Li X, Kunins HV, Roose RJ, Sohler NL. A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions. J Subst Abuse Treat Jun;40(4): Epub 2011 Feb 18. PMC d. Kattan J, Fox AD, Cunningham CO, Paone D, Harrison M, Kunins HV. Buprenorphine an office-based treatment for opioid use disorder. City Health information. 2015;34(1):1-8. Available at

3 2. Prescription Opioid Analgesics: Epidemiology, Management and Risks: I have conducted several studies examining prescription opioid analgesic management and risks. These studies have ranged from examining opioid analgesic management practices in a single health care system to examining trends in national data. Findings highlight the conflicts that providers have in balancing treatment of pain while limiting risk of opioids and how ill-prepared providers are in managing prescription opioids. In addition, while opioid-related overdoses continue to increase nationally, medical marijuana could play an important role in reducing the risk of opioid overdose. The latter findings have helped to guide states policies regarding medical marijuana. The impact of my work and expertise is demonstrated by being a member of the Opioid Guideline Workgroup for the CDC s Guideline for Prescribing Opioids for Chronic Pain, 2016 a. Bachhuber MA, Saloner B, Cunningham CO, Barry SL. Medical cannabis laws and opioid pain reliever overdose mortality in the United States, JAMA Intern Med Oct;174(10): PMC b. Bachhuber MA, Saloner B, Cunningham CO, Feingold J, Barry CL. Could Delaware s medical marijuana law reduce harms from opioid analgesics? Del Med J Nov;86(11): c. Sohler NL, Starrels JL, Khalid L, Jost J, Arnsten JH, Bachhuber MA, Cunningham CO. Marijuana use is associated with lower odds of prescription opioid analgesic use among HIV-infected individuals with chronic pain. J Pain Manag. Under review. d. Starrels JL, Wu B, Peyser D, Fox AD, Batchelder A, Barg F, Arnsten JH, Cunningham CO. It made my life a little easier: Understanding primary care providers use of opioid treatment agreements for patients with chronic pain. J Opioid Manag Mar-Apr;10(2): PMC Innovative HIV Treatment to Improve Access to and Retention in Care: As the founder and Director of the Montefiore/CitiWide Health Services Program which provided innovative health care to HIV-infected unstably-housed drug users, and PI on several grants that focused on outreach and retention in HIV care, my work has contributed significantly to examining innovative ways to improve access to and retention in HIV care, particularly focusing on marginalized populations. For example, the amount of outreach contacts, the person conducting the outreach, and the type of outreach all affect access and retention in care. This work has helped to guide outreach and retention policies and efforts supported by federal and local governments. In addition, my work has served as a model of an innovative and collaboration program between community-based organizations and academic medical centers. a. Cunningham CO, Sanchez JP, Heller D, Sohler NL. Assessment of a medical outreach program to improve access to HIV care among marginalized individuals. Am J Public Health Oct;97(10): PMC b. Cunningham CO, Buck J, Shaw F, Seigal L, Agins B. Factors associated with returning to HIV care after a gap in New York State. J Acquir Immune Defic Syndr Aug 1;66(4): PMC c. Blank AE, Fletcher J, Blackstock O, Verdecias N, Cunningham CO. Factors associated with retention and viral suppression among a cohort of HIV+ women of color. AIDS Patient Care STDS Jan;29 Suppl 1:S PMC d. Fox AD, Andersen MR, Bartlett G, Valverde J, Cunningham CO. Health outcomes and retention in care following release from prison for patients of an urban transitions clinic. J Health Care Poor Underserved Aug;25(3): PMC Enhancing HIV Testing and Prevention: As a mentor to several junior faculty members (including mentor on 5 NIHfunded career development awards), I have conducted several studies that focus on systematic efforts to enhance HIV testing and HIV prevention. These studies have included examining large systems and databases, including electronic medical records from academic medical centers and national data from methadone maintenance treatment programs. Key findings and concepts that have emerged from these studies include the lack of finding new HIV cases when implementing routine HIV testing, the importance of reframing HIV testing to target those with unknown status, and the lack of incorporation of HIV testing among drug treatment programs. a. Bachhuber MA, Cunningham CO. Changes over time in offering on-site testing for HIV, sexually transmitted infections, and hepatitis C virus in opioid treatment programs. JAMA Dec 25;310(24): PMC b. Bachhuber MA, Southern WN, Cunningham CO. Profiting and providing less care: comprehensive services at forprofit, nonprofit, and public opioid treatment programs in the United States. Med Care May;52(5): PMC c. Felsen UR, Bellin EY, Cunningham CO, Zingman BS. Development of an electronic medical record-based algorithm to identify patients with unknown HIV status. AIDS Care Oct;26(10): PMC d. Felsen UR, Cunningham CO, Heo M, Futterman DC, Weiss JM, Zingman BS. An expanded HIV testing strategy leveraging the electronic medical record uncovers undiagnosed infection among hospitalized patients. J Acquir Immune Defic Syndr May 1;75(1): PMC

4 Complete List of Published Work in MyBibliography (over 90 peer-reviewed articles): D. Research Support Ongoing grant Support NIDA K23DA PI: H. Perez (role: Mentor) 9/17 8/22 Project Title: Developing and pilot testing an intervention to increase opioid tapering in primary care Goal: This project will identify barriers and facilitators to opioid tapering, develop a tapering intervention, and using an RCT design, pilot test the feasibility and preliminary efficacy of the tapering intervention. NIDA K99DA PI: M. Akiyama (role: Mentor) 9/17 8/22 Project Title: Advance Care Coordination and Enhanced Linkage and Retention Among Transitional Re-Entrants Living with Hepatitis C-The HCV-ACCELERATE Trial Goal: To explore barriers to linkage to HCV care, and develop and pilot test an intervention to improve linkage to HCV care among individuals released from jail. NIMH K23MH PI: J. Ross (role: Mentor) 9/17 8/22 Project Title: Minimizing losses from HIV care under universal treatment in Rwanda Goal: To explore barriers to care, and develop and pilot test an intervention to improve HIV retention in care among HIV+ adults in Rwanda. NIDA K08DA PI: M. Bachhuber (role: Primary Mentor) 8/17 7/22 Project Title: Leveraging the electronic health record to reduce opioid analgesic prescriptions Goal: Using a cluster randomized trial to test whether changes in the default setting for opioid analgesic prescriptions in electronic health records reduces opioid analgesic prescriptions. NIDA R01DA PI: A. Fox (role: Co-Investigator) 7/17 6/22 Project Title: Buprenorphine treatment at syringe exchanges to reduce opioid misuse and HIV risk Goal: Using a randomized controlled trial to test whether buprenorphine treatment at a syringe exchange vs. community clinic reduces illicit opioid use and HIV risk behaviors. NIDA R01DA PI: Cunningham 7/17 6/22 Project Title: Does medical cannabis reduce opioid analgesics in HIV+ and HIV- adults with pain? Goal: To understand how medical cannabis use affects opioid analgesic use over time, with attention to THC/CBD content, HIV outcomes, and adverse events. CDC U01PS PI: O. Blackstock (role: Mentor/Co-Investigator) 5/17 4/21 Project Title: Development and pilot testing of a PrEP mobile outreach intervention for women Goal: In a collaborative community research partnership, we will develop and pilot test a mobile outreach intervention to promote PrEP uptake among women of color involved in transactional sex. NIAID P30AI PI: H. Goldstein (role: Co-Director, Development Core) 5/17 4/22 Project Title: Center for AIDS Research, Developmental Core Goal: To stimulate, coordinate, and support trans-institutional and transdisciplinary research to prevent new HIV infections, improve HIV treatment outcomes, and eradicate HIV reservoirs. and end the epidemic. NIDA R03DA PI: Cunningham 6/16 5/18 Project Title: Resilience in HIV-infected drug users Goal: To explore factors and behaviors that facilitate achieving VL suppression among active drug users. NIDA, R01DA PI: J. Starrels (role: Co-Investigator) 9/15 7/19 Project Title: Prescription opioid use, misuse, disorders and HIV outcomes Goal: To characterize prescription opioid use in HIV+ patients with chronic pain, examine the association between prescription opioid use and HIV outcomes. NIMH, K23MH PI: U. Felsen (role: Primary Mentor) 9/15 9/20 Project Title: TestED!: Applying implementation science to improve an HIV testing strategy for Emergency Departments

5 Goal: To use a structured, reproducible process guided by implementation science to improve the implementation of expanded HIV testing in emergency departments. NIDA, K23DA PI: B. Norton (role: Mentor) 9/15 8/20 Project Title: Adaptation and testing of a primary care HCV group medical treatment intervention Goal: To test the feasibility, acceptability, and preliminary efficacy of an intervention to improve hepatitis C treatment uptake among HIV-positive and negative injection drug users in primary care. NIDA, R34DA PI: A. Fox (role: Co-Investigator) 4/15-3/18 Project Title: Buprenorphine group medical visits for drug users at risk for HIV Goal: To develop and pilot test an intervention that uses group medical visits for individuals who continue to use opioids despite office-based buprenorphine treatment, examining its effect on drug use, retention, and HIV risk behaviors. NIDA, K24DA PI: Cunningham 4/14-3/19 Project Title: Mentoring researchers in drug abuse and HIV Goal: To provide mentorship to junior investigators focusing on drug abuse and HIV, targeting women and minorities. NIMH, K23MH PI: O. Blackstock (role: Primary Mentor) 3/14-2/19 Project Title: Development and Testing of an Adherence Intervention for HIV+ Women of Color Goal: To develop and pilot test a group-based intervention to improve HAART adherence among HIV+ women of color NIDA, R01DA PI: J. Shuter (role: Co-Investigator) 8/13-7/18 Project Title: trial of positively smoke free group therapy for HIV-infected smokers Goal: Using a randomized controlled trial design, this project will test whether a group-based smoking cessation intervention tailored to HIV-infected individuals is efficacious in achieving smoking cessation at 6 months. Grant Support Completed in the prior 3 years NIDA, R01DA PI: J. Arnsten (role: Co-Investigator) 8/12 6/17 Project Title: Neurocognitive effects of opiate agonist treatment in HIV-infected drug users Goal: Using a randomized controlled trial design, this project will test the neurocognitive effects of buprenorphine vs. methadone on HIV-positive and negative opioid-dependent individuals. NIDA, K23DA PI: A. Fox (role: Primary Mentor) 7/12 6/17 Project Title: Buprenorphine Facilitated Access and Supportive Treatment in Former Inmates Goal: To develop, test the feasibility of, and pilot test an intervention that uses peer navigators to improve access to buprenorphine treatment and provide support during treatment, targeting former inmates. NIDA, R01DA PI: Cunningham 7/11-4/17 Title: Abstinence reinforcing contingency management to suppress HIV viral load (Project FIRST) Goal: Using a RCT design, this project will test an abstinence-reinforcing contingency management intervention vs. performance feedback on HIV outcomes and drug treatment outcomes. NIDA R25DA PI: J. Arnsten (role: Co-Investigator/Mentor) 5/07-4/16 Title: Clinical Addiction Research and Education Program Goal: To provide education and research mentorship that focuses on HIV, substance use, and substance abuse and HIV treatment to physicians in training and junior faculty. NIDA, K23DA PI: J. Starrels (role: Primary Mentor) 9/10-8/15 Title: Intervention to Promote Opioid Treatment Agreements in Primary Care Goal: To develop, test the feasibility of, and pilot test the outcomes of an intervention that promotes the use of opioid treatment agreements between primary care providers and patients receiving chronic opioid analgesics. NIDA, R34DA PI: Cunningham 3/11-2/14 Title: Development of community-based buprenorphine treatment Goal: To develop and pilot test the feasibility and effectiveness of a community-based buprenorphine treatment intervention which will include education, access to treatment, and support during buprenorphine treatment.